FDA Approves Ingrezza for Huntington Disease Chorea
Nearly half of patients receiving Ingrezza saw a more than 40% reduction in Huntington disease chorea severity by the end of the treatment period.
Nearly half of patients receiving Ingrezza saw a more than 40% reduction in Huntington disease chorea severity by the end of the treatment period.
The designation was supported by initial interim safety and immunogenicity data from the phase 1b/2 ABATE trial.
SI-6603 is administered via a single, direct intradiscal injection.
Brexpiprazole is an atypical antipsychotic.
Donanemab is an investigational antibody therapy that targets a modified form of deposited amyloid-β peptide called N3pG.
The FDA has approved Qalsody (tofersen) for the treatment of adults with ALS who have a mutation in the SOD1 gene.
The NTX100 TOMAC System was previously granted the FDA’s Breakthrough Device designation.
RGX-202 is an investigational one-time gene therapy designed to deliver a transgene for a novel microdystrophin.
Tofersen is an investigational antisense medicine that reduces the synthesis of SOD1 protein production.
ABBV-951 is a solution of levodopa and carbidopa prodrugs for continuous subcutaneous delivery.